{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:50:21Z","timestamp":1795031421398,"version":"4.10.2"},"reference-count":62,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eculizumab is effective for complement-mediated thrombotic microangiopathy (CM-TMA), also known as atypical hemolytic uremic syndrome. Although lifelong therapy had been suggested, discontinuation does not universally lead to relapse. Comprehensive data evaluating risk factors for recurrence following discontinuation are limited. Our aim was to systematically review available literature assessing the role of complement genetic variants in this setting. Reports on CM-TMA and eculizumab withdrawal published before 1 January 2021, were included. Key reasons for patient exclusion were no follow-up after drug withdrawal and patients lacking complement genetic testing. Two-hundred eighty patients from 40 publications were included. Median age was 28 years, and 25 patients had a known history of renal transplant. Complement genetic variants were identified in 60%, most commonly in CFH (n\u00a0= 59) and MCP\/CD46 (n\u00a0= 38). Of patients with a complement gene variant, 51.3% had \u22651 likely pathogenic\/pathogenic variant whereas the remaining had variants of uncertain significance (VUS). Overall relapse rate after therapy discontinuation was 29.6%. Relapse rate was highest among patients with CFH variants and MCP\/CD46 variants in canonical splice regions. VUS (P\u00a0&amp;lt; .001) and likely pathogenic\/pathogenic variants (P\u00a0&amp;lt; .001) were associated with increased relapse. Presence of a renal allograft (P\u00a0=\u00a0.009); decreasing age (P\u00a0= .029); and detection of variants in CFH (P\u00a0&amp;lt; .001), MCP\/CD46 (P\u00a0&amp;lt; .001), or C3 (P\u00a0&amp;lt; .001) were all independently associated with relapse after eculizumab discontinuation. Eculizumab discontinuation is appropriate in specific patients with CM-TMA. Caution should be exerted when attempting such a strategy in patients with high\u00a0risk of recurrence, including a subgroup of patients with MCP\/CD46 variants.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006416","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T18:33:14Z","timestamp":1652121194000},"page":"340-350","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-9153","authenticated-orcid":false,"given":"Aldo A.","family":"Acosta-Medina","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"},{"name":"2Department of Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2590-7218","authenticated-orcid":false,"given":"Ann M.","family":"Moyer","sequence":"additional","affiliation":[{"name":"3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9318-7091","authenticated-orcid":false,"given":"Maria Alice V.","family":"Willrich","sequence":"additional","affiliation":[{"name":"3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-209X","authenticated-orcid":false,"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[{"name":"4Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"},{"name":"4Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6284-6269","authenticated-orcid":false,"given":"Christianne","family":"Bourlon","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Oncology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-3732","authenticated-orcid":false,"given":"Jeffrey L.","family":"Winters","sequence":"additional","affiliation":[{"name":"3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant M.","family":"Spears","sequence":"additional","affiliation":[{"name":"6Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra C.","family":"Bryant","sequence":"additional","affiliation":[{"name":"6Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7225-8228","authenticated-orcid":false,"given":"Meera","family":"Sridharan","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"issue":"7","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bjh.15899","article-title":"Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy","volume":"186","author":"Neave","year":"2019","journal-title":"Br J Haematol"},{"issue":"10","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"issue":"3","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination","volume":"13","author":"Struijk","year":"2013","journal-title":"Am J Transplant"},{"issue":"4","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ndt\/gfx196","article-title":"Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome","volume":"33","author":"Wijnsma","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome: the first year\u2019s experience","volume":"109","author":"Sheerin","year":"2015","journal-title":"QJM"},{"issue":"18","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/bloodadvances.2020003175","article-title":"Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome","volume":"5","author":"Chaturvedi","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10\u00a0cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00467-017-3813-2","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update","volume":"33","author":"Ardissino","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00467-014-2933-1","article-title":"Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency","volume":"29","author":"Michaux","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"2023021422371320600_","first-page":"45","article-title":"Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report","volume":"3","author":"Ohanian","year":"2011","journal-title":"Clin Pharmacol Adv Appl"},{"issue":"9","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1752-1947-8-307","article-title":"Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report","volume":"8","author":"Kourouklaris","year":"2014","journal-title":"J\u00a0Med Case Reports"},{"issue":"8","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1055\/s-0030-1262889","article-title":"New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab","volume":"36","author":"K\u00f6se","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00467-012-2276-8","article-title":"Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome","volume":"27","author":"Vilalta","year":"2012","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/TP.0b013e3181ccd80d","article-title":"Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation","volume":"89","author":"Larrea","year":"2010","journal-title":"Transplantation"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12882-020-01897-4","article-title":"Late renal recovery after treatment over 1 year post-onset in an atypical hemolytic uremic syndrome: a case report","volume":"21","author":"Kuroki","year":"2020","journal-title":"BMC Nephrol"},{"issue":"3","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"sfw115","DOI":"10.1093\/ckj\/sfw115","article-title":"Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome","volume":"10","author":"Macia","year":"2017","journal-title":"Clin Kidney J"},{"issue":"5","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"e1385","DOI":"10.1542\/peds.2011-1685","article-title":"Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report","volume":"130","author":"Giordano","year":"2012","journal-title":"Pediatrics"},{"issue":"8","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/j.1432-2277.2012.01497.x","article-title":"Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft","volume":"25","author":"Alachkar","year":"2012","journal-title":"Transpl Int"},{"issue":"8","key":"2023021422371320600_","first-page":"1421","article-title":"Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome","volume":"93","author":"Ca\u00f1igral","year":"2014","journal-title":"Ann Hematol"},{"issue":"5","key":"2023021422371320600_","first-page":"641","article-title":"Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management","volume":"28","author":"De Sousa Amorim","year":"2015","journal-title":"J\u00a0Nephrol"},{"issue":"8","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00277-013-1972-1","article-title":"Successful discontinuation of eculizumab therapy in a patient with aHUS","volume":"93","author":"Pu","year":"2013","journal-title":"Ann Hematol"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol"},{"issue":"3","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00467-017-3612-9","article-title":"Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS","volume":"32","author":"Hackl","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex\u00a0vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/nep.12937","article-title":"Absence of thrombocytopaenia and\/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation","volume":"22","author":"Krishnan","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"2023021422371320600_","first-page":"950","article-title":"A\u00a0case report and literature review of eculizumab withdrawal in atypical hemolytic-uremic syndrome","volume":"17","author":"Quiroga","year":"2016","journal-title":"Am\u00a0J\u00a0Case Rep"},{"issue":"6","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00467-015-3078-6","article-title":"A\u00a0complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab","volume":"30","author":"Schalk","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"suppl 1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/nep.12931","article-title":"Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab","volume":"22","author":"Choo","year":"2017","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"2023021422371320600_","first-page":"532","article-title":"Discontinuation of eculizumab in a patient with atypical hemolytic uremic syndrome due to a mutation in CFH","volume":"67","author":"Habbig","year":"2016","journal-title":"Am\u00a0J\u00a0Kidney Dis"},{"issue":"3","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1097\/MPH.0000000000000505","article-title":"Disease recurrence after early discontinuation of eculizumab in a patient with atypical hemolytic uremic syndrome with complement C3 I1157T mutation","volume":"38","author":"Toyoda","year":"2016","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"31","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"e4330","DOI":"10.1097\/MD.0000000000004330","article-title":"Can eculizumab be discontinued in aHUS?","volume":"95","author":"Sahutoglu","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/ijn.IJN_336_18","article-title":"Successful treatment of anti-factor H antibody-associated atypical hemolytic uremic syndrome","volume":"30","author":"Kise","year":"2020","journal-title":"Indian J Nephrol"},{"issue":"2","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00467-020-04714-0","article-title":"Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis","volume":"36","author":"Kl\u00e4mbt","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12882-020-01847-0","article-title":"Ten-year outcome of eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome: a single center experience","volume":"21","author":"Kant","year":"2020","journal-title":"BMC Nephrol"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.transproceed.2019.10.015","article-title":"Atypical hemolytic uremic syndrome after kidney transplantation: lessons learned from the good, the bad, and the ugly. A case series with literature review","volume":"52","author":"Fayek","year":"2020","journal-title":"Transplant Proc"},{"issue":"4","key":"2023021422371320600_","first-page":"1373","article-title":"Eculizumab interruption in atypical hemolytic uremic syndrome due to shortage: analysis of a Brazilian cohort","volume":"34","author":"Neto","year":"2021","journal-title":"J\u00a0Nephrol"},{"issue":"6","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00277-012-1622-z","article-title":"Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation","volume":"92","author":"Carr","year":"2012","journal-title":"Ann Hematol"},{"issue":"2","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.ajkd.2014.04.039","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome","volume":"65","author":"Wetzels","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00467-012-2283-9","article-title":"Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation","volume":"27","author":"Cayc\u0131","year":"2012","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ndtplus\/sfr157","article-title":"Early treatment with eculizumab in atypical haemolytic uraemic syndrome","volume":"5","author":"Garjau","year":"2012","journal-title":"Clin Kidney J"},{"issue":"5","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00467-013-2416-9","article-title":"Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab","volume":"28","author":"Gulleroglu","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/ckj\/sft065","article-title":"Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab","volume":"6","author":"Gilbert","year":"2013","journal-title":"Clin Kidney J"},{"issue":"2","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/ckj\/sfs185","article-title":"Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice","volume":"6","author":"Delmas","year":"2013","journal-title":"Clin Kidney J"},{"issue":"1","key":"2023021422371320600_","first-page":"111","article-title":"Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH\/CFHR1-3 and complement factor H 479","volume":"12","author":"Chaudhary","year":"2014","journal-title":"Blood Transfus"},{"issue":"7809","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"issue":"7","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","article-title":"Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy","volume":"200","author":"Osborne","year":"2018","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ng.2892","article-title":"A\u00a0general framework for estimating the relative pathogenicity of human genetic variants","volume":"46","author":"Kircher","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","article-title":"REVEL: an ensemble method for predicting the pathogenicity of rare missense variants","volume":"99","author":"Ioannidis","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"5","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"22","key":"2023021422371320600_","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.2021012037","article-title":"Functional characterization of 105 Factor H variants associated with aHUS: lessons for variant classification","volume":"138","author":"Martin Merinero","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/3\/340\/2033441\/blooda_adv-2021-006416-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/3\/340\/2033441\/blooda_adv-2021-006416-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T07:51:43Z","timestamp":1700553103000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/3\/340\/485194\/Complement-gene-variant-effect-on-relapse-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006416","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]}}}